On September 15,1997, the FDA released a press state ment regarding the immediate withdrawal from the mar ket of fenfluramine (Pondamin) and dexfenfluramine (Redux). 1 The press release stated mat "companies have agreed to voluntarily withdraw their drugs." This course of action was based on findings that "approximately 30% of patients evaluated had abnormal echocardiograms." Both fenfluramine and dexfenfluramine had been linked with the occurrence of another serious medical problem, primary pulmonary hypertension (PPH). PPH is characterized when the pulmonary vasculature sus tains remodeling. These changes may lead to an increase in pulmonary artery pressure and pulmonary vascular resistance. PPH is associated with a median survival time of 2.6 years from the time of diagnosis. 2 The causal rela tionship is unknown with these drugs. Postmarketing surveillance has shown that dexfenfluramine has been associated with 100 cases of PPH, from which 14 patients have died. 3 Patients had been receiving dexfenfluramine for a mean ± SD of 1.2 ± 1.3 years prior to developing PPH. Additionally, several cases of PPH have also been associated with fenfluramine. 4
On September 15,1997, the FDA released a press state ment regarding the immediate withdrawal from the mar ket of fenfluramine (Pondamin) and dexfenfluramine (Redux). 1 The press release stated mat "companies have agreed to voluntarily withdraw their drugs." This course of action was based on findings that "approximately 30% of patients evaluated had abnormal echocardiograms." Both fenfluramine and dexfenfluramine had been linked with the occurrence of another serious medical problem, primary pulmonary hypertension (PPH). PPH is characterized when the pulmonary vasculature sus tains remodeling. These changes may lead to an increase in pulmonary artery pressure and pulmonary vascular resistance. PPH is associated with a median survival time of 2.6 years from the time of diagnosis. 2 The causal rela tionship is unknown with these drugs. Postmarketing surveillance has shown that dexfenfluramine has been associated with 100 cases of PPH, from which 14 patients have died. 3 Patients had been receiving dexfenfluramine for a mean ± SD of 1.2 ± 1.3 years prior to developing PPH. Additionally, several cases of PPH have also been associated with fenfluramine. 4 Echocardiography is a recorded ultrasound image of the heart designed to assess heart valve function. Valvu lar heart disease was recently identified in 24 women who had no history of cardiac disease. These results were published in the New England Journal of Mediane in Au gust 1997. 5 These women had been prescribed the drug combination of phentermine and fenfluramine, common ly known as "phen-fen," and were evaluated more than 1 year after initiation of therapy. Echocardiograms re vealed that all the women showed unusual valvular physiology and regurgitation. Eight women demonstrated PPH. Several patients were concomitantly taking sero tonin-augmenting antidepressant agents including fluox etine, sertraline, and paroxetine, known as selective sero-...potential withdrawal effects from the abrupt discontinuation of these agents may have been overlooked.
• tonin-reuptake inhibitors (SSRIs). The mechanism of ac tion of the SSRIs includes selectively inhibiting the reup take of serotonin, which may be the same or similar to the mechanism of action of fenfluramine. Serotonin is a neurotransmitter found in the brain and the periphery; increased concentrations of serotonin in the periphery have been associated with valvular disease. 6 Additional ly, the use of methysergide and ergotamine has been shown to cause valvular disease. 7 Dexfenfluramine's package insert was revised from its original contents, including a larger chance of developing PPH than previously suspected (23-46 cases /million vs. 18 cases/million)* 9 ; however, the risk of developing PPH secondary to obesity is associated with two times the risk of a nonobese patient Due to the severity of these adverse effects and the ur gency associated with taking fenfluramine and dexfen fluramine off the market, potential withdrawal effects from the abrupt discontinuation of these agents may have been overlooked.
The potential for serious health problems is greater in patients who are considered obese (body mass index 30 or 27-30 kg/m 2 ). Obesity may lead to significant medical consequences such as hypertension, diabetes, hypercho-lesterolemia, arthritis, and chronic respiratory disease. The above disease states can increase the risk of morbidi ty and mortality. Weight loss can lower the risk of devel oping these problems secondary to obesity. 340 Nonpharmacologic therapy for short-term treatment of obesity, such as diet modification and exercise, have been only moderately successful.
Pharmacologic agents have been used as appetite sup pressants for more than 50 years with or without sup portive measures such as dietary modification and exer cise. 10 The pharmacologic agents that have been most successful include the indirect-acting sympamomimetic amines, such as phentermine, and agents that enhance serotonin activity. These drugs include the serotonergic agonists, such as fenfluramine and dexfenfluramine, and the SSRIs, such as fluoxetine and sertraline.
Dexfenfluramine is the D-isomer of fenfluramine. In the brain, both drugs inhibit the neuronal reuptake of serotonin into presynaptic nerve endings. In addition, the active metabolite of dexfenfluramine, ^norfenfluramine, increases the release of serotonin into the brain synapses by a direct action on postsynaptic neurons. There is also evidence that the peripheral increase in serotonin concen tration produced by these drugs may significantly in crease thermogenesis, as seen following the ingestion of carbohydrate-rich meals, which can cause an increase in muscle glucose intake, potentially lowering blood sug ar. 3 
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There have been reports 11 " 17 of withdrawal symptoms and discontinuation syndromes associated with the abrupt discontinuation of serotonergic agents such as the SSRIs, trazodone, venlafaxine, and tricyclic antidepressants. Withdrawal symptoms from these agents may include dizziness/light-headedness, insomnia, fatigue/lethargy, nausea, headache, sensory disturbances, hypomania, dethe journal of Pharmacy pression, irritability, aggression, hallucinations, and suici dal ideation. Since fenfluramine and dexfenfluramine both possess serotonergic agonist activity, it would be expected that abrupt discontinuation of these drugs could evoke with drawal symptoms similar to those listed above. With re gard to the serotonergic antidepressants, agents with half-lives of less than 24 hours (i.e., paroxetine, fluvoxamine) are more likely to have withdrawal symptoms than are agents with longer half-lives (i.e., fluoxetine). 12 The approximate 20-hour half-lives of fenfluramine and dexfenfluramine also support the possibility of having withdrawal effects. 818 In fact, fenfluramine has been re ported to be associated with a discontinuation syndrome characterized by depression, sleep disturbances, anxiety, malaise, headache, and drowsiness. 1318 ' 19 The withdrawal syndrome associated with the abrupt discontinuation of serotonin agonists may be overlooked or misdiagnosed as flu or migraine headache for several reasons. First, symptoms may range from very mild to severe. Second, patients with moderate-to-severe symp toms may not associate them with drug therapy or physicians may not be aware that withdrawal symptoms may occur. It has also been suggested that the withdraw al syndromes associated with opiates, alcohol, nicotine, and anxiolytics such as the benzodiazepines may be, at least in part, associated with serotonin. 20 Given the previous discussion of the possible adverse events that may occur on the abrupt discontinuation of the serotonergic agents fenfluramine and dexfenfluramine, the following recommendations are presented to rrdnirnize and manage the symptoms of the medication withdrawal. For mild symptoms, the provider's reassur ance may assist the patient in understanding and coping with the current situation; this may be the only interven tion required. Informing the patients prior to the discon tinuation of the medication would have been ideal, to help prepare them for the possible withdrawal symp toms. Some patients may require a reinstitution of the discontinued agent to alleviate the symptoms and then a slow taper, possibly with weekly reductions of 25-50% of the daily dose (i.e., from 60 to 30 to 15 mg/d, each for a week between reductions), will minimize the discomfort. Since ferifluramine and dexfenfluramine have been pulled off the market and are no longer available for a slow taper, it may be necessary to substitute another serotonergic agent with a longer half-life, such as fluoxe tine. Fluoxetine has been used to alleviate a withdrawal phenomenon in cases of patients experiencing these symptoms from discontinuation of other serotonergic agents with a shorter half-life, as seen with paroxetine and venlafaxine. 12 Benzodiazepines may offer some symptomatically focused (i.e., insomnia, anxiety, restless ness) treatment for certain patients. Since most with drawal symptoms will persist for 1-3 weeks, the use of these agents may not be needed on a regular or protract ed basis. In conclusion, physicians, pharmacists, and pa tients should be educated regarding the potential for and recognition of the possible withdrawal symptoms that may occur with serotonergic agents as a whole and specifically fenfluramine and dexfenfluramine to mini mize patient discomfort on abrupt discontinuation. -
